(Reuters) – Alnylam Pharmaceuticals Inc and Regeneron Pharmaceuticals Inc on Monday agreed to partner to develop treatments for eye and central nervous system diseases using RNA interference.
Regeneron will make a $400 million upfront payment to Alnylam and to purchase $400 million of Alnylam equity at a price per share of $90.
Alnylam is eligible to receive up to an additional $200 million in milestone payments upon achievement of certain criteria during early clinical development for the programs.
Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Maju Samuel
Our Standards:The Thomson Reuters Trust Principles.
source: reuters.com